Hexafluorenium
A neuromuscular blocking agent that inhibits plasma cholinesterase and potentiates the effects of succinylcholine, extending the duration of muscle paralysis during surgical procedures. It was used in anesthesia practice to allow lower doses of succinylcholine to be used while maintaining adequate relaxation. Its use in modern anesthesia has been largely supplanted by newer neuromuscular blocking agents.
Peso molecular
502,7000 g/mol
LogP
7,60
TPSA
0,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21
InChI
InChI=1S/C36H42N2/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3/q+2
Molecular Formula
C36H42N2+2
HBD / HBA
- / -
Enlaces Rotables
9
Átomos Pesados
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A neuromuscular blocking agent that inhibits plasma cholinesterase and potentiates the effects of succinylcholine, extending the duration of muscle paralysis during surgical procedures. It was used in anesthesia practice to allow lower doses of succinylcholine to be used while maintaining adequate relaxation. Its use in modern anesthesia has been largely supplanted by newer neuromuscular blocking agents.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Hexafluorenium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201349. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3601. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexafluorenium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexafluorenium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexafluorenium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexafluorenium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexafluorenium"></drugfyi-drug>